Latest Milestone Payments News

Carnegie Clean Energy has made significant strides in its wave energy technology, progressing the ACHIEVE Programme and launching a €4 million EU-funded project to reduce costs, while securing a prestigious Defence innovation award.

Kairos Minerals wraps up its largest drilling campaign at Mt York, revealing promising gold zones and signing a key mining agreement with the Nyamal people, while gearing up for a resource update and further exploration.

QPM Energy has secured key contracts and financing milestones for its 112MW Isaac Power Station, while managing stable gas supply amid weak electricity prices.

Pilot Energy has made significant strides in Q4 2025 with the launch of a modular data centre joint venture, progress on a hybrid solar and battery project, and advancement of offshore gas exploration partnerships, supported by substantial new financing.

Fluence Corporation Limited has reported a robust FY 2025 with a 52.3% revenue increase and record new orders, driven by a strategic pivot to higher-margin Smart Product Solutions and recurring revenue streams.

Lunnon Metals has secured unconditional status for its Ore Purchase Agreement with Gold Fields and approved mining at Lady Herial, backed by a robust feasibility study projecting strong cash flows. Exploration continues aggressively across its gold and nickel projects in Western Australia.

Micro-X Ltd has secured a historic $3.3 million order for its Rover mobile X-ray units in Malaysia, alongside a $6.2 million capital raise to fuel its expanding medical imaging and security technology pipeline.

Immutep Limited has entered a strategic collaboration with Dr. Reddy’s, receiving a A$30 million upfront payment and potential milestones up to A$528 million, while reporting promising clinical progress across multiple cancer immunotherapy trials.

DXN Limited reported a 63% revenue decline in Q2 FY26 due to project delays but bolstered its future outlook with a $15 million backlog and a strategic joint venture in Indonesia.

Syntara Limited has made significant strides in its clinical pipeline, launching new trials and receiving key regulatory designations, positioning 2026 as a pivotal year for the company.

Starpharma reports strong progress in strategic collaborations and internal drug development, alongside a 70% surge in Viraleze™ online sales and a solid $18.2 million cash position.

Dimerix Limited has completed recruitment for its pivotal ACTION3 Phase 3 trial targeting a rare kidney disease, secured positive FDA feedback on trial endpoints, and reported a solid cash position of AU$38.5 million at the end of 2025.